Polatuzumab vedotin, an anti-CD79b antibody-drug conjugate for the treatment of relapsed/refractory diffuse large B-cell lymphoma
- PMID: 32954807
- DOI: 10.2217/fon-2020-0675
Polatuzumab vedotin, an anti-CD79b antibody-drug conjugate for the treatment of relapsed/refractory diffuse large B-cell lymphoma
Abstract
Refractory/relapsed diffuse large B-cell lymphoma remains a major unmet medical need with poor outcome, especially for patients considered ineligible for stem cell transplant. Polatuzumab vedotin (PV) is a first-in-class anti-CD79b antibody-drug conjugate that contains the microtubule inhibitor monomethyl auristatin E. The development of PV is currently very active. This drug was US FDA approved in 2019 in combination with bendamustine and rituximab for the treatment of refractory/relapsed diffuse large B-cell lymphoma in third line and more, after demonstrating relevant efficacy and acceptable safety in a pivotal randomized Phase II trial. This review summarizes the features of this new drug with the primary focus on the clinical work supporting efficacy, relevance and tolerability of PV.
Keywords: CD79b; antibody–drug conjugate; diffuse large B-cell lymphoma; polatuzumab vedotin.
Similar articles
-
An evaluation of polatuzumab vedotin for the treatment of patients with diffuse large B-cell lymphoma.Expert Rev Hematol. 2020 Sep;13(9):933-942. doi: 10.1080/17474086.2020.1795828. Epub 2020 Aug 10. Expert Rev Hematol. 2020. PMID: 32700586 Review.
-
Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.Lancet Oncol. 2015 Jun;16(6):704-15. doi: 10.1016/S1470-2045(15)70128-2. Epub 2015 Apr 27. Lancet Oncol. 2015. PMID: 25925619 Clinical Trial.
-
Polatuzumab Vedotin: a New Target for B Cell Malignancies.Curr Hematol Malig Rep. 2020 Apr;15(2):125-129. doi: 10.1007/s11899-020-00572-7. Curr Hematol Malig Rep. 2020. PMID: 32172360 Review.
-
Polatuzumab vedotin: an investigational anti-CD79b antibody drug conjugate for the treatment of diffuse large B-cell lymphoma.Expert Opin Investig Drugs. 2020 Oct;29(10):1079-1088. doi: 10.1080/13543784.2020.1800638. Epub 2020 Aug 12. Expert Opin Investig Drugs. 2020. PMID: 32700972 Review.
-
Polatuzumab vedotin for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma.Expert Opin Biol Ther. 2021 Jul;21(7):831-839. doi: 10.1080/14712598.2020.1777979. Epub 2020 Jun 15. Expert Opin Biol Ther. 2021. PMID: 32500753 Review.
Cited by
-
Mechanisms of Therapeutic Antitumor Monoclonal Antibodies.Cancer Res. 2021 Sep 15;81(18):4641-4651. doi: 10.1158/0008-5472.CAN-21-1109. Epub 2021 Jun 18. Cancer Res. 2021. PMID: 34145037 Free PMC article. Review.
-
[Efficacy and safety of Polatuzumab Vedotin in combination with rituximab plus bendamustine in patients with relapsed/refractory diffuse large B-cell lymphoma: a single center analysis].Zhonghua Xue Ye Xue Za Zhi. 2022 Jan 14;43(1):66-69. doi: 10.3760/cma.j.issn.0253-2727.2022.01.013. Zhonghua Xue Ye Xue Za Zhi. 2022. PMID: 35231996 Free PMC article. Chinese. No abstract available.
-
A real-world pharmacovigilance study of polatuzumab vedotin based on the FDA adverse event reporting system (FAERS).Front Pharmacol. 2024 Jun 25;15:1405023. doi: 10.3389/fphar.2024.1405023. eCollection 2024. Front Pharmacol. 2024. PMID: 38983914 Free PMC article.
-
A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapy.Blood Adv. 2022 May 10;6(9):2757-2762. doi: 10.1182/bloodadvances.2021006801. Blood Adv. 2022. PMID: 35240681 Free PMC article.
-
Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress.J Hematol Oncol. 2021 Jun 5;14(1):88. doi: 10.1186/s13045-021-01097-z. J Hematol Oncol. 2021. PMID: 34090506 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
